Abstract
ABSTRACTINTRODUCTION: The aim of this study was to evaluate the essential effects of cholinesterase inhibitors between the first days of the medication and after 1 month in the patients have not the history of disease, the patients not used the medicines which effect the sleep or the patients started new medication.METHODS: Patients diagnosed with mild to moderate stage Alzheimer’s disease according to DSM-IV criteria (age: 55–85) were admitted in this multi-centred study between December 2014 and January 2017. Thirty five patients with mini mental test score between 14 and 24 were included in the study. Pittsburgh Sleep Quality Index (PSQI), Cornell Scale for Depression in Dementia (CSDD), Beck Anxiety Scale (BAS) and Standardized Mini Mental Test (SMMT) were given to all patients were used in first days of treatment and at least after 1 month.RESULTS: Twenty patients (57%) were using Donepezil and 15 patients (43%) were using Rivastigmine. Gender, marital status, educational status and family history of...
Highlights
The aim of this study was to evaluate the essential effects of cholinesterase inhibitors between the first days of the medication and after 1 month in the patients have not the history of disease, the patients not used the medicines which effect the sleep or the patients started new medication
We intended to detect the exact influence of cholinesterase inhibitors on sleep quality, which are frequently used in patients with Alzheimer’s disease (AD)
AD patients are frequently treated with medications that influence quality of sleep negatively, due to behavioural and psychiatric symptoms
Summary
The aim of this study was to evaluate the essential effects of cholinesterase inhibitors between the first days of the medication and after 1 month in the patients have not the history of disease, the patients not used the medicines which effect the sleep or the patients started new medication. DISCUSSION: When donepezil and rivastigmine were compared in this study, it was observed that they had similar positive effects on sleeping quality, but there was not statistically significant difference. AD patients may experience insomnia symptoms such as REM sleep behaviour disorder, sleeping difficulty, intermittent sleeping, early morning awakening, and sleep apnoea or excessive daytime sleepiness which emerges as a result of insomnia. These sleep disorders are important as risk factors in the development of psychiatric symptoms as well as their effects on life quality, functional and cognitive capabilities [4]. In these studies, the population of the patients are seen to use the medicines affecting sleep
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
